Annals On Call – Tirzepatide Versus Intensified Conventional Care for Poorly Controlled Type 2 Diabetes

Centor RM, Batch BC

Annals of internal medicine, 2026;:e2603906OC

Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)

Cavender MA, Jastreboff AM, Cheng AYY, et al.

American heart journal, 2026;:107626

Severe Euglycemic Diabetic Ketoacidosis After Semaglutide-Associated Poor Intake Despite Empagliflozin Discontinuation: A Case Report

Niknam K, Niknam T

International medical case reports journal, 2026;19:650090

Post-Initiation Care Patterns and Weight Loss With Semaglutide and Tirzepatide for Obesity in Clinical Practice

Yang H, Kim C, Ross JS, et al.

medRxiv : the preprint server for health sciences, 2026

[Two trials, one result: oral semaglutide does not slow cognitive decline in early Alzheimer disease.]

Kurotschka PK, Barry H

Recenti progressi in medicina;117(10):472-473

In brief: A cardiovascular indication for tirzepatide (Mounjaro)

The Medical letter on drugs and therapeutics;68(1765):167

Practical Considerations for the Use of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity: A Clinician-Oriented Guide

Alp GT, Gökçay Canpolat A

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2026

Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction

Elbatreek MH, Li Z, Yu X, et al.

European heart journal, 2026

Effects of GLP-1 receptor agonists on aesthetic surgery practice: A contemporary review

Ersan M, Özturhan O

Turkish journal of surgery, 2026

Bidirectional Pharmacology of GIP Receptor Targeting in Obesity: Historical Foundations, Mechanistic Divergence, and Translational Boundaries

Liu C, Wang Y, Liu J, et al.

Peptides, 2026;:171524

Biologic Injection-Related Pain in Severe Asthma, Its Impact on Treatment Aversion, and Pain-Relief Approach: A Multicenter Observational Study

Matsumoto T, Aizawa-Abe M, Yamamoto N, et al.

The journal of allergy and clinical immunology. In practice, 2026

Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes

Al-Nusair M, Khurana S, Eysha M, et al.

Journal of diabetes and metabolic disorders, 2026;25(2):280

Endocrine determinants of MASLD: mechanisms and therapeutic targets

Chaturvedi R, Mathew A, Pradhan A, et al.

Frontiers in endocrinology, 2026;17:1967494

Durability of Semaglutide Effects After Treatment Discontinuation in HIV-Associated Lipohypertrophy: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Clinical Trial

Adekunle RO, Wu Q, Sattar A, et al.

Open forum infectious diseases, 2026;13(10):ofag631

Potential Physiological Convergence Between GLP-1 Receptor Signaling and Hepatocyte TAZ in Metabolic Liver Disease: From Metabolic Homeostasis to Fibrotic Remodeling

Gholam MF

Cells, 2026;15(19)

Comorbid Cardiovascular-Liver Disease Disparities: Current Understanding and Future Directions

Hafez A, Nour M, Ibrahim R, et al.

Current cardiology reports, 2026;28(1)

Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort study

Nielsen VW, Holgersen N, Pedersen NH, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2026

Semaglutide Demonstrates Benefits Across Frailty Levels

Anderer S

JAMA, 2026

Detection and Excretion Profiling of Semaglutide Use in Human Urine by UHPLC-HRMS for Anti-Doping Purpose

Tian T, Chen X, Deng X

Drug testing and analysis, 2026

Tirzepatide attenuates cardiac microvascular injury and ferroptosis-related lipid peroxidation in diabetic mice: endothelial responses in the context of partial PRKN silencing

Lu G, Wang X, Zhuang H, et al.

European journal of pharmacology, 2026;:179387